MYOKARDIA, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 28th, 2015 • MyoKardia Inc • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of April 20, 2015, by and among MyoKardia, Inc., a Delaware corporation (the “Company”), and each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
License and Collaboration Agreement by and between MyoKardia, Inc. and Aventis Inc.License and Collaboration Agreement • September 28th, 2015 • MyoKardia Inc • Pharmaceutical preparations • New York
This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is made as of August 1, 2014 (the “Effective Date”), by and between MyoKardia, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 400 East Jamie Court, Suite 102, South San Francisco, CA 94080, USA (“MyoKardia”), and Aventis Inc., a corporation organized and existing under the laws of Pennsylvania, having offices at 55 Corporate Drive in Bridgewater, New Jersey 08807 (“Sanofi”). Sanofi and MyoKardia are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
